Positive News SentimentPositive NewsNASDAQ:NVCT Nuvectis Pharma (NVCT) Stock Price, News & Analysis → Claim Your FREE 'AI Income Playbook' Now! (From The Oxford Club) (Ad) Free NVCT Stock Alerts $6.77 -0.06 (-0.88%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$6.51▼$6.8950-Day Range$5.98▼$8.1452-Week Range$5.85▼$18.46Volume51,266 shsAverage Volume82,154 shsMarket Capitalization$124.27 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Nuvectis Pharma alerts: Email Address Nuvectis Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside210.2% Upside$21.00 Price TargetShort InterestBearish16.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$80,471 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.29) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.84 out of 5 starsMedical Sector638th out of 915 stocksPharmaceutical Preparations Industry301st out of 430 stocks 3.5 Analyst's Opinion Consensus RatingNuvectis Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuvectis Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Nuvectis Pharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.53% of the float of Nuvectis Pharma has been sold short.Short Interest Ratio / Days to CoverNuvectis Pharma has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvectis Pharma has recently increased by 14.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuvectis Pharma does not currently pay a dividend.Dividend GrowthNuvectis Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVCT. Previous Next 2.7 News and Social Media Coverage News SentimentNuvectis Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nuvectis Pharma this week, compared to 1 article on an average week. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvectis Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $80,471.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders38.85% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvectis Pharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nuvectis Pharma are expected to decrease in the coming year, from ($1.29) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvectis Pharma is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvectis Pharma is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvectis Pharma has a P/B Ratio of 9.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nuvectis Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubClaim Your FREE "AI Income Playbook" Now!Income expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Nuvectis Pharma Stock (NASDAQ:NVCT)Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Read More NVCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCT Stock News HeadlinesMay 16, 2024 | insidertrades.comNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Acquires $13,075.60 in StockMay 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 20, 2024 | entrepreneur.comThe Veteran Pharma Founders That Keep Buying Their Own NASDAQ StockMay 16, 2024 | seekingalpha.comNuvectis Pharma: An Interesting Early Pipeline Does Not Justify A BuyMay 16, 2024 | globenewswire.comNuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 8, 2024 | markets.businessinsider.comStrong Buy Rating for Nuvectis Pharma on Robust Financials and Promising Oncology Drug TrialsMay 8, 2024 | finance.yahoo.comNuvectis Pharma Inc Reports Q1 2024 Financial OutcomesMay 7, 2024 | investorplace.comNVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024April 17, 2024 | finance.yahoo.comIs Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?April 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)April 8, 2024 | finanznachrichten.deNuvectis Pharma, Inc.: Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 8, 2024 | markets.businessinsider.comNuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick FactsApril 8, 2024 | finance.yahoo.comNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 8, 2024 | globenewswire.comNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 2, 2024 | investorplace.com5 Healthcare Stocks to Buy for 2024March 21, 2024 | finance.yahoo.comInsider Buys Additional US$51k In Nuvectis Pharma StockMarch 19, 2024 | globenewswire.comNuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research MeetingMarch 15, 2024 | msn.comNuvectis reports initial data from Phase Ib ovarian cancer trialMarch 15, 2024 | marketwatch.comNuvectis Pharma Shares Rise 11% After Positive Preliminary Data for Cancer TreatmentMarch 15, 2024 | globenewswire.comNuvectis Pharma to Present at the 36th Annual Roth ConferenceMarch 14, 2024 | globenewswire.comNuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian CancerMarch 6, 2024 | investorplace.comNVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023March 5, 2024 | finance.yahoo.comNuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical ProgressFebruary 19, 2024 | finance.yahoo.comNuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownershipFebruary 9, 2024 | morningstar.comNuvectis Pharma Inc NVCTSee More Headlines Receive NVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/15/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NVCT CUSIPN/A CIK1875558 Webwww.nuvectis.com Phone201-614-3150FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+210.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-141.57% Return on Assets-103.98% Debt Debt-to-Equity RatioN/A Current Ratio3.46 Quick Ratio3.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book9.67Miscellaneous Outstanding Shares18,360,000Free Float11,225,000Market Cap$124.30 million OptionableNot Optionable Beta0.49 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Ron Bentsur M.B.A. (Age 58)Co-Founder, Chairman, CEO & President Comp: $1.12MDr. Enrique Poradosu Ph.D. (Age 57)Co-Founder, Executive VP, Chief Scientific & Business Officer Comp: $705.5kMr. Shay Shemesh (Age 40)Co-Founder, Executive VP, Chief Development & Operations Officer Comp: $705.5kMr. Michael Carson CPA (Age 48)Vice President of Finance Key CompetitorsOculisNASDAQ:OCSNeurogeneNASDAQ:NGNEAcelyrinNASDAQ:SLRNLexicon PharmaceuticalsNASDAQ:LXRXTerns PharmaceuticalsNASDAQ:TERNView All CompetitorsInsiders & InstitutionsRon BentsurBought 1,940 shares on 5/14/2024Total: $13,075.60 ($6.74/share)Ron BentsurBought 2,000 shares on 5/10/2024Total: $12,800.00 ($6.40/share)Enrique PoradosuBought 500 shares on 5/10/2024Total: $3,145.00 ($6.29/share)Vanguard Group Inc.Bought 4,517 shares on 5/10/2024Ownership: 1.626%Blue Zone Wealth Advisors LLCBought 14,350 shares on 4/18/2024Ownership: 0.081%View All Insider TransactionsView All Institutional Transactions NVCT Stock Analysis - Frequently Asked Questions Should I buy or sell Nuvectis Pharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectis Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NVCT shares. View NVCT analyst ratings or view top-rated stocks. What is Nuvectis Pharma's stock price target for 2024? 1 brokerages have issued twelve-month target prices for Nuvectis Pharma's stock. Their NVCT share price targets range from $21.00 to $21.00. On average, they expect the company's share price to reach $21.00 in the next year. This suggests a possible upside of 210.2% from the stock's current price. View analysts price targets for NVCT or view top-rated stocks among Wall Street analysts. How have NVCT shares performed in 2024? Nuvectis Pharma's stock was trading at $8.34 at the beginning of 2024. Since then, NVCT shares have decreased by 18.8% and is now trading at $6.77. View the best growth stocks for 2024 here. When is Nuvectis Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our NVCT earnings forecast. How were Nuvectis Pharma's earnings last quarter? Nuvectis Pharma, Inc. (NASDAQ:NVCT) posted its earnings results on Tuesday, May, 7th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.15. When did Nuvectis Pharma IPO? Nuvectis Pharma (NVCT) raised $19 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share. Who are Nuvectis Pharma's major shareholders? Nuvectis Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.63%) and Blue Zone Wealth Advisors LLC (0.08%). Insiders that own company stock include Enrique Poradosu, Kenneth Hoberman, Marlio Charles Mosseri, Ron Bentsur and Shay Shemesh. View institutional ownership trends. How do I buy shares of Nuvectis Pharma? Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NVCT) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.